Evofem Biosciences Announces Uplisting to OTCQB
Evofem Biosciences Announces Uplisting to OTCQB
SAN DIEGO, Oct. 3, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB: EVFM) announced today that the trading of its common shares has been upgraded to the OTCQB Venture Market from the OTC Pink Open Market. The Company's ticker symbol remains the same.
聖地牙哥, 二零二二年十月三日 /PRNews社/-伊芙姆生物科學股份有限公司（OTCQB：EVFM）今天宣布，其普通股的交易已從場外粉紅公開市場升級到 OTCQB 風險投資市場。本公司的股票代號保持不變。
The women's health focused biotech company developed and commercializes Phexxi® (lactic acid, citric acid, potassium bitartrate), the first and only FDA-approved hormone-free, contraceptive vaginal gel.
這家專注於女性健康的生物技術公司開發並將 Pexxi®（乳酸，檸檬酸，酒石酸鉀）商業化，這是第一個也是唯一 FDA 批准的無激素避孕陰道凝膠。
Phexxi net sales have increased for three consecutive quarters; the Company expects that third quarter results, due in mid-November, will continue this trend. Net product sales of the hormone-free contraceptive had already surpassed 2021 levels in the first half of 2022.
PHexxi 淨銷售額連續三個季度增長；公司預計 11 月中旬到期的第三季度業績將繼續這一趨勢。在 2022 年上半年，無激素避孕藥的淨產品銷售額已超過 2021 年的水平。
Evofem is on track to report top-line data in mid-October 2022 from its registrational Phase 3 clinical trial evaluating Phexxi for the prevention of chlamydia and gonorrhea in women. Positive study outcomes would enable regulatory submissions and potential approval for these potential new indications in 2023. If approved by the FDA, Phexxi will be the first woman-controlled prescription prophylactic against chlamydia and gonorrhea, which are a significant and growing public health concern.
Evofem 正在通過以下方式報告頂線數據 2022 年十月中旬 評估 Pexxi 用於預防女性衣原體和淋病的註冊 3 期臨床試驗。積極的研究結果將使監管機構提交意見書並可能在 2023 年獲得這些潛在新適應症的批准。如果獲得 FDA 批准，Pexxi 將成為第一個針對衣原體和淋病的女性控制處方預防劑，這是公共衛生重要且日益增長的問題。
Preliminary CDC data for 2021 show that infections with chlamydia and gonorrhea continued to increase during the second year of the COVID-19 pandemic, with no signs of slowing.
2021 年的 CDC 初步數據顯示，衣原體和淋病的感染在 COVID-19 大流行的第二年繼續增加，沒有放緩的跡象。
The OTCQB Venture Market provides investors an exchange-comparable information experience with convenient trading through their preferred broker or financial advisor. Listed companies are current in their reporting and undergo an annual verification and management certification process. Investors can find Real-Time quotes and market information at .
OTCQB 風險投資市場通過他們首選的經紀人或財務顧問為投資者提供便捷的交易體驗，為投資者提供交易所可比較的信上市公司目前正在進行報告，並經過年度驗證和管理認證流程。投資者可在以下網站找到實時報價和市場信息。
About Evofem Biosciences
Evofem Biosciences, Inc. is developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. The Company's first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. The Company expects to report top-line data in October 2022 from its registrational Phase 3 clinical trial evaluating Phexxi for the prevention of chlamydia and prevention of gonorrhea in women. Learn more at phexxi.com and evofem.com.
關於伊芙姆生物科學
Evofem Biosciences, Inc. 正在開發和商業化創新產品，以解決女性性和生殖健康中未滿足的需求。該公司首個 FDA 批准的產品 Pexxi®（乳酸，檸檬酸和酒石酸鉀），是一種無激素的按需處方避孕陰道凝膠。它裝在一盒 12 個預先填充的塗藥器中，並在每次性行為之前 0-60 分鐘應用。該公司預計將於 2022 年 10 月報告頂級數據，從評估 Pexxi 用於預防女性衣原體和預防淋病的第三期臨床試驗。如需瞭解更多資訊，請前往相關網站和 Evofem.com。
Phexxi® is a registered trademark of Evofem Biosciences, Inc.
河南省 PHXI®是 Evofem 生物科學公司的註冊商標
Forward-Looking Statements
This press release includes "forward-looking statements," within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 including, without limitation, statements related to expected financial results and the anticipated impact of the potential results of the Company's registrational Phase 3 trial. Various factors could cause actual results to differ materially from those discussed or implied in the forward-looking statements, including market and other conditions, and you are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements, or that could impair the value of Evofem Biosciences' assets and business, are disclosed in the Company's SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2021, its Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, and subsequent filings. All forward-looking statements are expressly qualified in their entirety by such factors. The Company does not undertake any duty to update any forward-looking statement except as required by law.
前瞻性陳述
本新聞稿包括經修訂的《1934 年證券交易法》第 21E 條提供的安全港前瞻性陳述所指的「前瞻性陳述」，以及 1995 年《私人證券訴訟改革法》，包括但不限於與預期財務業績相關的陳述以及公司註冊第三期審判的潛在結果的預期影響。各種因素可能導致實際結果與前瞻性聲明（包括市場和其他條件）中討論或暗示的結果有很大不同，並且您被警告不要過度依賴這些前瞻性陳述，而這些前瞻性陳述僅在本新聞稿發布日期為止。這些前瞻性陳述中的每一項都涉及風險和不確定性。可能導致實際業績與前瞻性聲明中討論或暗示的重要因素有重大差異，或可能損害 Evofem Biosciences 資產和業務價值的重要因素，在公司的 SEC 文件中披露，包括截至 2021 年 12 月 31 日，其截至 2022 年 6 月 30 日和隨後的 10-Q 表的年度報告，其截至 2021 年 12 月 31 日的 10-K 表年報。所有前瞻性陳述均通過這些因素明確完全符合條件。除法律要求外，本公司不承擔任何更新任何前瞻性聲明的責任。
Contacts
联系人
Investors:
Amy Raskopf
SVP, Investor Relations
Evofem Biosciences, Inc.
[email protected]
(917) 673-5775
投資者：
艾米·拉斯科夫
投資者關係資深副總裁
伊芬生物科學股份有限公司
[電子郵件保護]
(917) 673-5775
Media:
[email protected]
媒體:
[電子郵件保護]
SOURCE Evofem Biosciences, Inc.
來源伊芙姆生物科學有限公司
譯文內容由第三人軟體翻譯。